Purpose The purpose of this study was to describe the long-term results of AlphaCor implantations, and to evaluate the main complications and risk factors. Methods Retrospective analysis of preoperative and follow-up data from 15 AlphaCor implantations. Analysis of outcomes, trends, and associations was performed and compared with data from published clinical trials and a literature review.Results The survival rate of the device at 1, 2, and 3 years was 87%, 58%, and 42%, respectively. Postoperative visual acuity ranged from hand movement to 0.8. The most significant complications were stromal melt (nine cases), optic deposition (three eyes), and retroprosthetic membrane formation (three eyes). The most common device-unrelated complication was trauma (three patients). All complications were managed without loss of the eye. Conclusion AlphaCor provides a treatment option for patients with corneal blindness in which a donor tissue graft would not succeed.
Purpose: To evaluate the extent of posterior capsule opacification (PCO) following cataract surgery-torsional phacoemulsification with liquefaction method removal of the epithelial cells (right eye), and straight forward torsional phacoemulsification (left eye), with subsequent implantation of the AcrySof SA60AT intraocular lens. Methods: In this prospective clinical trial patients with bilateral cataract were observed. The Evaluation of Posterior Capsule Opacification (EPCO) 2000 software and the Open-Access Systematic Capsule Assessment (OSCA) system were used for PCO assessment at 3, 6, 12 and 24 months after surgery. Postoperative changes in endothelial cell count (ECC) and pachymetry were also evaluated.
Purpose Posterior capsule opacification (PCO) is still one of the most common complication following cataract surgery with IOL implantation. We evaluate the extent of PCO after cataract surgery ‐ torsional phacoemulsification and Liquifaction method removal of the epithelial cells (right eye) and torsional phacoemulsification (left eye). For PCO quantification we use two types of software. Methods In our prospective clinical study we examine patients 3, 6, 12 and 24 months after surgery, digital retroillumination photographs of the anterior segment, pachymetry, endothelial cell count (ECC) and best corrected visual acuity (BCVA) are obtained For evaluation of PCO we use EPCO 2000 software (Evaluation of Posterior Capsule Opacification) and OSCA software (Open‐Access Systematic Capsule Assessment). Results The BCVA two years postoperatively is 0.896 ± 0.13 (right eye), 0.883 ± 0.16 (left eye). Nd‐YAG laser capsulotomy one year after surgery underwent one patient (both eyes) and one patient two years postoperatively (right eye). EPCO results ‐ right eye: 0.260 ± 0.198 (3M); 0.259 ± 0.173 (6M); 0.308 ± 0.19 (12M); 0.419 ± 0.252 (24M), left eye: 0.279 ± 0.170 (3M); 0.280 ± 0.153 (6M); 0.333 ± 0.197 (12M); 0.480 ± 0.313 (24M) OSCA results ‐ right eye: 0.599 ± 0.240 (3M); 0.605 ± 0.333 (6M); 0.598 ± 0.256 (12M); 0.655 ± 0.402 (24M), left eye: 0.627 ± 0.403 (3M); 0.635 ± 0.360 (6M); 0.629 ± 0.328 (12M); 0.654 ± 0.452 (24M). Conclusion The Liquifaction method is save for occular tissue. One year after surgery most cases of PCO is graded as minimal. Supported in part by Charles University Grant Agency, No. 103809
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.